FDA Inspection 1158637 — GlaxoSmithKline Research & Development Limited
The FDA completed an inspection of GlaxoSmithKline Research & Development Limited on May 16, 2017 in Stevenage. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- May 16, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Stevenage (United Kingdom)
Additional Details
Mutual Recognition Agreement (MRA)